

Dr. Howard Chertkow – Additional Background and Accomplishments

LEADERSHIP

NATIONAL:

- 2001-2005. Served as the **elected President of C5R** (Consortium of Canadian Centres for Clinical Cognitive Research), a consortium of 32 Canadian centres carrying out Alzheimer Disease clinical research in Canada. Helped transform this into a professional vehicle for international drug studies of AD in Canada. Played an important role in the development of clinical trials on dementia in Canada.
- Served as **Coordinator (2007) of the 3rd Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD3)**, which brought together geriatricians, psychiatrists, and neurologists to draw up new national guidelines. Important role in uniting the physicians working with dementia into a cohesive group with a consensus approach to treatment.

INTERNATIONAL:

- Served as **Chairman of the Scientific Committee of the Alzheimer's Disease International** meeting for 2011.
- 2013-2018 Member of the **Executive Committee of the NIH-funded Alzheimer's Disease Neuroimaging Initiative (ADNI)**, representing the Canadian government and CIHR.
- 2012-2016 Elected an **Executive member of ISTAART** (Alzheimer's Association International Society To Advance Alzheimer's Research and Treatment), an international society for AD research, which organizes the annual international Alzheimer's Disease meeting.

SIGNIFICANCE OF CONTRIBUTIONS

- Dr. Chertkow's research has been funded continuously by MRC and CIHR since 1990. His work on semantic loss in Alzheimer Disease, and the phenomenon of "hyperpriming" which derives from it, have been seminal in the cognitive neuroscience field, and have directly influenced current work on semantics by European researchers (e.g., Lambon Ralf, Giffard). The three top papers on Semantic Memory (in Brain, Brain and Language, and Cognitive Neuropsychology) have together been cited 891 times.
- Headed up the team that developed the MoCA (Montreal Cognitive Assessment). This 12 minute screening tool for Mild Cognitive Impairment (MCI) is used in clinics in USA, Europe and Australia, Korea, Thailand, and China. This paper (2005) received

the Thomson Reuters' Essential Science Indicator award as "Most Cited paper in Mild Cognitive Impairment, 2006-2009." It has been cited over 6,500 times. Moreover, the MoCA has become the standard for assessment of MCI and mild memory loss in clinics around the world - it has been translated into 37 languages. The MoCA was named in a CIHR publication as one of the seven most important contributions of Canadian researchers in the field of dementia.

- Received the 2008 national Irma M Parhad Award from the C5R for "Excellence in Alzheimer's Disease research".

PRODUCTIVITY

Developing the concepts of Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI).

Advancing the modern early diagnosis of dementia and MCI are important and Dr. Chertkow has been a key national and international researcher in promulgating diagnostic concepts and bringing them to the medical community. He was the only Canadian playing a significant role in developing the new NIA guidelines for dementia and AD. He chaired and co-chaired the Canadian Third and Fourth dementia Consensus Conferences.

FUNDING

Recipient of \$40 million in research funding as Principal Investigator. This includes being awarded the first CIHR Foundation grant in the domain of aging and geriatrics.

2017-18 The W. Garfield Weston Foundation - \$149,325.00. Chertkow, H. (P.I.), Roncero, T., & Thiel, A. Developing tDCS as a therapy for Alzheimer Disease and Frontotemporal dementia.

2016-2021 CIHR (Canadian Institutes of Health Research) New Directions in Dementia Research: Big Data on Dementia Grant of \$4,750,000.00. Chertkow, H., Hogan, D., Smith, E., Rockwood, K., Phillips, N. et al. Broad and deep analyses in neurodegeneration (BRAIN).

2015-2023 CIHR (Canadian Institutes of Health Research) Foundation operating grant of \$1,695,052.00. Chertkow, H. (P.I.), A. Evans, H. Feldman, E. Nikelski, H. Paudel, C. Roncero, H. Schipper, N. Sourial, & A. Thiel. Typical and atypical Alzheimer Disease: salivary tau biomarkers, therapy with neuromodulation, and disease subtypes.

2014-2019 CIHR (Canadian Institutes of Health Research) and Partners - 33.5 million/5 years. Chertkow, H. (Scientific Director). Canadian Consortium on Neurodegeneration in Aging (CCNA).

2014-15 The W. Garfield Weston Foundation - \$149,745.00. Chertkow, H. (P.I.), Paudel, H., Schipper, H. & Gornitsky, M. Development and validation of salivary tau as a biomarker for early Alzheimer's Disease.